Inositol phosphoglycan P-type in preeclampsia: A novel marker?

Hypertension

Volumn 49, Issue 1, 2007, Pages 84-89

  Williams, Philip J ^a   Gumaa, Khalid ^b   Scioscia, Marco ^a,c   Redman, Christopher W ^d   Rademacher, Thomas W ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARABIAN GULF UNIVERSITY   (Bahrain)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biological marker; Inositol phosphoglycan; Insulin resistance; Preeclampsia; Screening test

Indexed keywords

BIOLOGICAL MARKER; GLYCAN DERIVATIVE; INOSITOL PHOSPHOGLYCAN TYPE P; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; INOSITOL PHOSPHATE; INOSITOL PHOSPHATE GLYCAN; POLYSACCHARIDE;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; SCREENING; URINALYSIS; METHODOLOGY; PREGNANCY; RISK FACTOR; URINE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INOSITOL PHOSPHATES; POLYSACCHARIDES; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 33847666793     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000251301.12357.ba     Document Type: Article

References (30)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799.
2. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism. 1999;48:892-896.
3. Martinez AE, Gonzalez OM, Quinones GA, Ferrannini E. Hyperinsulinemia in glucose-tolerant women with preeclampsia. A controlled study. Am J Hypertens. 1996;9:610-614.
4. Goldman M, Kitzmiller JL, Abrams B, Cowan RM, Laros RK Jr. Obstetric complications with GDM. Effects of maternal weight. Diabetes. 1991;40(suppl 2):79-82.
5. Kunjara S, Greenbaum AL, Wang DY, Caro HN, McLean P, Redman CW, Rademacher TW. Inositol phosphoglycans and signal transduction systems in pregnancy in preeclampsia and diabetes: evidence for a significant regulatory role in preeclampsia at placental and systemic levels. Mol Genet Metab. 2000;69:144-158.
6. Paine MA, Scioscia M, Gumaa KA, Rodeck CH, Rademacher TW. P-type inositol phosphoglycans in serum and amniotic fluid in active preeclampsia. J Reprod Immunol. 2006;69:165-179.
7. Scioscia M, Gumaa K, Kunjara S, Paine MA, Selvaggi LE, Rodeck CH, Rademacher TW. Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and -2. J Clin Endocrinol Metab. 2006;91:709-717.
8. Frick W, Bauer A, Bauer J, Wied S, Muller G. Structure-activity relationship of synthetic phosphoinositolglycans mimicking metabolic insulin action. Biochemistry. 1998;37:13421-13436.
9. Varela-Nieto I, Leon Y, Caro HN. Cell signalling by inositol phosphoglycans from different species. Comp Biochem Physiol B Biochem Mol Biol. 1996;115:223-241.
10. Arkwright PD, Rademacher TW, Dwek RA, Redman CW. Pre-eclampsia is associated with an increase in trophoblast glycogen content and glycogen synthase activity, similar to that found in hydatidiform moles. J Clin Invest. 1993;91:2744-2753.
11. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
12. Paine MA, Rodeck CH, Williams PJ, Rademacher TW. Possible involvement of inositol phosphoglycan-P in human parturition. J Reprod Immunol. 2003;59:267-275.
13. Cywinski J. The Essentials in Pressure Monitoring. Boston, MD: Martinus Nijhoff Publishers; 1980.
14. Kunjara S, Wang DY, Greenbaum AL, McLean P, Kurtz A, Rademacher TW. Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changes. Mol Genet Metab. 1999;68:488-502.
15. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol. 1991;165:1667-1672.
16. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta. 2003;24(suppl A):S21-S27.
17. Kaaja R, Laivuori H, Pulkki P, Tikkanen MJ, Hiilesmaa V, Ylikorkala O. Is there any link between insulin resistance and inflammation in established preeclampsia? Metabolism. 2004;53:1433-1435.
18. Muller G, Wied S, Piossek C, Bauer A, Bauer J, Frick W. Convergence and divergence of the signaling pathways for insulin and phosphoinositolglycans. Mol Med. 1998;4:299-323.
19. Shashkin PN, Shashkina EF, Fernqvist-Forbes E, Zhou YP, Grill V, Katz A. Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia. 1997;40:557-563.
20. Scioscia M, Vimercati A, Selvaggi LE, Rodeck CH, Rademacher TW. Inositol phosphoglycan putative insulin mediator in human amniotic fluid. J Matern Fetal Neonatal Med. 2006;19:9-12.
21. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594.
22. Goswami D, Tannetta DS, Magee LA, Fuchisawa A, Redman CW, Sargent IL, von Dadelszen P. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006;27:56-61.
23. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension. 2004;43:988-992.
24. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 2004;104:1367-1391.
25. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
26. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005;293:77-85.
27. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061-1066.
28. Ferrazzani S, Caruso A, De Carolis S, Martino IV, Mancuso S. Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol. 1990;162:366-371.
29. Lilley K, Zhang C, Villar-Palasi C, Larner J, Huang L. Insulin mediator stimulation of pyruvate dehydrogenase phosphatases. Arch Biochem Biophys. 1992;296:170-174.
30. Asplin I, Galasko G, Larner J. chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A. 1993;90:5924-5928.